Antisense Oligonucleotides Targeting miR-133a in Osteosarcoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteosarcoma, particularly targeting cancer stem cells, are limited, and there is a need for new therapeutic approaches since existing therapies do not effectively address the drug resistance and metastasis associated with CD133-expressing cells in osteosarcoma.
Innovation Solution
The use of antisense molecules specific for microRNAs miR-1, miR-10b, and miR-133a, particularly stabilized RNA or locked nucleic acid oligonucleotides, to target and regulate the expression of these microRNAs in CD133-expressing osteosarcoma cells, enhancing chemotherapy efficacy and reducing drug resistance and invasiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat osteosarcoma, then tumor growth is inhibited, but drug resistance develops in CD133-expressing cancer stem cells
Solution Approach 1:
The patent extracts and targets specific microRNAs (miR-1, miR-10b, miR-133a) that are overexpressed in CD133-expressing cancer stem cells. By using antisense molecules to specifically bind to and inhibit these microRNAs, the treatment selectively addresses the resistant stem cell population without broadly affecting all tumor cells, thereby overcoming drug resistance while maintaining chemotherapy efficacy
Solution Approach 2:
The patent changes the molecular parameter of microRNA expression levels in CD133-expressing cells by introducing antisense molecules. This parameter change (reducing miR-1, miR-10b, and miR-133a expression) leads to decreased drug resistance and enhanced sensitivity to conventional chemotherapy agents, resolving the contradiction between maintaining chemotherapy efficacy and preventing drug resistance
2Reliability
If conventional chemotherapy is used to treat osteosarcoma, then tumor growth is controlled, but metastasis is promoted by CD133-expressing cells
Solution Approach 1:
The patent specifically extracts and targets the metastasis-promoting microRNAs (miR-1, miR-10b, miR-133a) that are overexpressed in CD133-expressing cancer stem cells. By using antisense molecules to inhibit these specific microRNAs, the treatment eliminates the metastatic potential of stem cells while maintaining tumor control through conventional chemotherapy
Solution Approach 2:
The patent changes the expression parameter of specific microRNAs in CD133-expressing cells, reducing miR-1, miR-10b, and miR-133a levels. This parameter change decreases the invasiveness and metastatic capability of tumor cells while preserving the tumor control achieved by conventional chemotherapy
3Adaptability or versatility
If no targeted therapy is available for osteosarcoma, then treatment options are limited, but conventional chemotherapy provides some survival benefit
Solution Approach 1:
The patent introduces antisense molecules as intermediary agents that specifically target and inhibit microRNAs in CD133-expressing cancer stem cells. These antisense molecules act as mediators between conventional chemotherapy and the resistant stem cell population, enhancing the overall effectiveness of treatment and improving survival rates by combining existing chemotherapy with targeted microRNA inhibition
Solution Approach 2:
The patent creates a composite treatment approach by combining conventional chemotherapy agents with antisense molecules targeting specific microRNAs. This composite strategy addresses both the bulk tumor cells (through chemotherapy) and the resistant stem cell population (through antisense molecules), thereby expanding treatment options and improving overall survival outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted regulation of miR-1, miR-10b, and miR-133a in osteosarcoma cells reduces drug resistance, invasiveness, and tumorigenicity, offering a potential new therapeutic strategy for treating osteosarcoma by enhancing the effectiveness of conventional chemotherapeutic agents.
Implementation Method 1
an antisense molecule specific for a microRNA (miRNA) selected from miR-1, miR-10b, and miR-133a
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR- 133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.